- Home
- APLM
APLM
Apollomics Inc.
as 12-18-2024 4:00pm EST
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 15.6M | IPO Year: | N/A |
| Target Price: | $425.00 | AVG Volume (30 days): | 106.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -62.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.50 - $105.00 | Next Earning Date: | 08-14-2024 |
| Revenue: | $2,101,000 | Revenue Growth: | 70.54% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Apollomics Inc. News
APLM Breaking Stock News: Dive into APLM Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
GlobeNewswire
a month ago
Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
GlobeNewswire
3 months ago
Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
GlobeNewswire
3 months ago
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire
4 months ago
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
GlobeNewswire
4 months ago
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
GlobeNewswire
4 months ago
Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
GlobeNewswire
5 months ago
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
Compare APLM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APLM Apollomics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.